A recent study indicates that Provigil can help in the treatment of apathy in Alzheimer’s disease. It is a wakefulness promoting medication and is prescribed to treat excessive sleepiness that is caused due to narcolepsy, sleep apnea or by shift work sleep disorder. The drug works by altering the natural chemicals known as neurotransmitters in the brain.
In this blog, you can learn more about Provigil and also about its action for apathy in Alzheimer’s disease. The study also focuses on the performance of the activities of daily living, shortly termed as ADL and also about caregiver burden in those who are having this problem.
Research on Provigil for treatment of apathy in Alzheimer’s disease
This study has evaluated the efficacy of pharmacological treatment of apathy in patients who have been suffering from Alzheimer’s disease. A systematic literature search was conducted on those clinical trials that were published in order to assess the effects of pharmacological treatment on lack of interest in patients with the above problem for the past ten years.
About 23 participants were involved in the study were having mild to moderate AD and also stroke AD and other criteria that are related to the disorder were randomized with Provigil 200mg or with controlled placebo groups. All of the participants were also receiving doses of cholinesterase inhibitor medicine.
The participants completed the assessment after about eight months of treatment. The resultant outcome included family report measures of apathy, caregiver burden, and ADL performance in addition to direct evaluation of ADL performance.
The experimental group and the group that was on placebo portrayed reduction in unconcern between the baseline and final assessment. It was also noted that there was no significant additional reduction in their lack of interest with this drug.
Both the groups did not show significant changes in caregiver report of ADL performance over time. The study showed that there was a trend towards improved levels of concern that is being related to reduce levels of caregiver burden.
Resultant outcome of the study conducted
The inclusion of Provigil or its generic component Modafinil to the standard care treatment did not result in significant additional reactions in apathy or improvement in the functioning of ADL. The reduction was noted in reported apathy that was observed in both the groups between baseline and final assessment was due to the effect of the placebo. The reactions in perceived apathetic symptomatology were however correlated with reductions in reported caregiver distress and burden. In order to confirm the absence of significant effects, larger studies were required with more statistical power. One has to take Modafinil or Provigil only if they are prescribed by their physician and have to take it exactly as advised.